Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 17:4:108.
doi: 10.3389/fcell.2016.00108. eCollection 2016.

Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer

Matthew J Riese  1 , Edmund K Moon  2 , Bryon D Johnson  3 , Steven M Albelda  2
Affiliations
Review

Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer

Matthew J Riese et al. Front Cell Dev Biol. .

Abstract

Diacylglycerol kinases (DGKs) are a family of enzymes that catalyze the metabolism of diacylglycerol (DAG). Two isoforms of DGK, DGKα, and DGKζ, specifically regulate the pool of DAG that is generated as a second messenger after stimulation of the T cell receptor (TCR). Deletion of either isoform in mouse models results in T cells bearing a hyperresponsive phenotype and enhanced T cell activity against malignancy. Whereas, DGKζ appears to be the dominant isoform in T cells, rationale exists for targeting both isoforms individually or coordinately. Additional work is needed to rigorously identify the molecular changes that result from deletion of DGKs in order to understand how DAG contributes to T cell activation, the effect of DGK inhibition in human T cells, and to rationally develop combined immunotherapeutic strategies that target DGKs.

Keywords: CD8+ T cell; T cell receptor; diacylglycerol; diacylglycerol kinase; immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model of enhanced T cell activity in DGK-deficient T cells. DGKα and DGKζ function to metabolize DAG generated downstream of TCR activation. Deletion of either or both isoforms results in T cells with enhanced TCR signal transduction downstream of DAG and resultant enhanced effector functions (“No inhibitor”). Loss of DGK confers resistance to inhibitory pathways that function through direct interference of TCR signal transduction, since these inhibitory events occur proximal to generation of DAG (“Direct TCR Inhibitor”). We predict that T cells deficient in DGKs remain sensitive to inhibitory pathways that mediate their effect independent of interference with TCR signal transduction (“Non-TCR Inhibitor”), or for pathways that inhibit TCR signaling at rate limiting steps downstream of DAG formation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Almena M., Andrada E., Liebana R., Merida I. (2013). Diacylglycerol metabolism attenuates T-cell receptor signaling and alters thymocyte differentiation. Cell Death Dis. 4, e912. 10.1038/cddis.2013.396 - DOI - PMC - PubMed
    1. Arumugam V., Bluemn T., Wesley E., Schmidt A. M., Kambayashi T., Malarkannan S., et al. . (2015). TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β. J. Leukoc. Biol. 98, 703–712. 10.1189/jlb.2HIMA1214-578R - DOI - PMC - PubMed
    1. Baldanzi G., Pighini A., Bettio V., Rainero E., Traini S., Chianale F., et al. . (2011). SAP-mediated inhibition of diacylglycerol kinase α regulates TCR-induced diacylglycerol signaling. J. Immunol. 187, 5941–5951. 10.4049/jimmunol.1002476 - DOI - PMC - PubMed
    1. Byrne K. T., Vonderheide R. H., Jaffee E. M., Armstrong T. D. (2015). Special conference on tumor immunology and immunotherapy: a new chapter. Cancer Immunol. Res. 3, 590–597. 10.1158/2326-6066.CIR-15-0106 - DOI - PMC - PubMed
    1. Callahan M. K., Postow M. A., Wolchok J. D. (2016). Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069–1078. 10.1016/j.immuni.2016.04.023 - DOI - PubMed